Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?
- 4 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 135 (1), 17-28
- https://doi.org/10.1007/s10549-012-2033-5
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Monitoring neoadjuvant chemotherapy in breast cancer patients: Improved MR assessment at 3 T?Journal of Magnetic Resonance Imaging, 2011
- Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and RecommendationsNeoplasia, 2009
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant TherapyJournal of Clinical Oncology, 2008
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006Annals Of Oncology, 2007
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- Neoadjuvant chemotherapy for operable breast cancerBritish Journal of Surgery, 2007
- Monitoring therapeutic efficacy in breast carcinomasEuropean Radiology, 2006
- Apparent Diffusion Coefficient: a quantitative parameter for in vivo tumor characterizationEuropean Journal of Radiology, 2003
- Diffusion Magnetic Resonance Imaging: an Early Surrogate Marker of Therapeutic Efficacy in Brain TumorsJNCI Journal of the National Cancer Institute, 2000